This is therefore a contrasting of the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership in Vital Therapies Inc. (NASDAQ:VTL) and Arcus Biosciences Inc. (NYSE:RCUS). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vital Therapies Inc.	N/A	0.00	53.60M	-1.27	0.00
Arcus Biosciences Inc.	8.04M	57.72	50.51M	-1.18	0.00

Table 1 highlights Vital Therapies Inc. and Arcus Biosciences Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Vital Therapies Inc. and Arcus Biosciences Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Vital Therapies Inc.	0.00%	-167.4%	-132.2%
Arcus Biosciences Inc.	-628.23%	0%	0%

Liquidity

3.3 and 3.3 are the respective Current Ratio and a Quick Ratio of Vital Therapies Inc. Its rival Arcus Biosciences Inc.’s Current and Quick Ratios are 16 and 16 respectively. Arcus Biosciences Inc. has a better chance of clearing its pay short and long-term debts than Vital Therapies Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Vital Therapies Inc. and Arcus Biosciences Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Vital Therapies Inc.	0	2	0	2.00
Arcus Biosciences Inc.	0	0	0	0.00

Vital Therapies Inc. has a 1,550.58% upside potential and a consensus target price of $3.25.

Institutional & Insider Ownership

Roughly 20.6% of Vital Therapies Inc. shares are owned by institutional investors while 40% of Arcus Biosciences Inc. are owned by institutional investors. Insiders owned roughly 0.1% of Vital Therapies Inc.’s shares. Insiders Comparatively, owned 0.9% of Arcus Biosciences Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Vital Therapies Inc.	-14.66%	-22.53%	-96.12%	-94.88%	-94.6%	-95.46%
Arcus Biosciences Inc.	10.68%	12.26%	-2.69%	-21.59%	0%	-25.65%

For the past year Arcus Biosciences Inc. has weaker performance than Vital Therapies Inc.

Summary

On 8 of the 10 factors Arcus Biosciences Inc. beats Vital Therapies Inc.

Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patientÂ’s own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.